ABSTRACT
Objective@#To explore the molecular mechanism of resveratrol (RES) in the treatment of oral squamous cell carcinoma (OSCC) through the use of biological information methods such as network pharmacology and molecular docking and to provide a theoretical reference for the clinical application of RES in the treatment of OSCC.@*Methods@#The Swiss Target Prediction(http://www.swisstargetprediction.ch), SEA (http://sea.bkslab.org)database, and Pharm mapper database(http://lilab-ecust.cn) were used to retrieve RES-related targets, and the DISGENET (www.disgenet.org), OMIM (https://omim.org) and GeneCards (https://www.genecards.org) databases were used to screen OSCC disease targets. The intersection of drugs and disease targets was determined, and Cytoscape 3.7.2 software was used to construct a "drug-diseasetarget pathway" network. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used to construct a target protein interaction network, and the DAVID database was used for enrichment analysis of key proteins. Finally, molecular docking validation of key proteins was performed using AutoDock and PyMOL. The enrichment analysis and molecular docking results were integrated to predict the possible molecular mechanisms of RES treatment in OSCC; western blot was used to determine the effect of resveratrol at different concentrations (50, 100) μmol/L on the expression of Src tyrosine kinase (SRC), epidermal growth factor receptor (EGFR), estrogen receptor gene 1 (ESR1), and phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway proteins in OSCC HSC-3 cells.@*Results@#A total of 243 targets of RES drugs and 6 094 targets of OSCC were identified. A total of 116 potential common targets were obtained by intersecting drugs with disease targets. These potential targets mainly participate in biological processes such as in vivo protein self-phosphorylation, peptide tyrosine phosphorylation, transmembrane receptor protein tyrosine kinase signaling pathway, and positive regulation of RNA polymerase Ⅱ promoter transcription, and they interfere with the PI3K/AKT signaling pathway to exert anti-OSCC effects. The docking results of resveratrol with OSCC molecules indicated that key targets, such as EGFR, ESR1, and SRC, have good binding activity. The results of cell-based experiments showed that resveratrol inhibited the protein expression of SRC, EGFR, ESR1, p-PI3K, and p-AKT in HSC-3 cells in a dose-dependent manner.@*Conclusion@#RES can inhibit the expression of its targets EGFR, ESR1, SRC, p-PI3K, and p-AKT in OSCC cells.
ABSTRACT
@#[摘 要] 目的：检测长链非编码RNA（long non-coding RNA，lncRNA）ARHGAP5-AS1在乳腺癌组织及细胞中的表达，分析其表达与患者临床病理参数及预后的相关性，并初步探讨其对乳腺癌细胞体外增殖、迁移和侵袭的影响。方法：通过对TCGA数据库中乳腺癌相关数据集的生物信息学分析，筛选出在乳腺癌中低表达且与患者不良预后相关的lncRNA ARHGAP5-AS1，采用qPCR方法在江南大学附属医院肿瘤科从2010年4月至2016年10月收集的乳腺癌组织中验证其表达。采用χ2检验分析ARHGAP5-AS1表达与乳腺癌患者临床病理参数之间的关系，Kaplan-Meier生存分析构建生存曲线，比较高、低表达组的总生存期和无复发生存期。CCK-8实验、划痕实验和Transwell实验分别检测ARHGAP5-AS1敲低对乳腺癌细胞MDA-MB-231和BT-549的增殖、迁移和侵袭的影响。结果：TCGA数据库分析结果显示，ARHGAP5-AS1在乳腺癌组织中的表达水平显著低于正常乳腺组织（P<0.01），其低表达与较大肿瘤直径（T3）、远处转移（M1）、ER和PR阴性以及较短的总生存期显著相关（均P<0.05）。乳腺癌组织中ARHGAP5-AS1表达水平显著低于癌旁组织（P<0.05），其低表达与较大的肿瘤直径和淋巴结转移相关（均P<0.05）。同样，ARHGAP5-AS1在6株人乳腺癌细胞系（MDA-MB-231、BT-549、MDA-MB-468、MCF-7、HCC1937、Hs578T）中的表达水平也显著低于正常乳腺上皮细胞系（MCF-10A）（均P<0.05）。细胞功能实验显示，ARHGAP5-AS1敲低促进MDA-MB-231和BT-549细胞的增殖、迁移和侵袭（均P<0.05）。结论：ARHGAP5-AS1异常低表达可能通过促进乳腺癌细胞的增殖、迁移和侵袭影响乳腺癌的发生发展。
ABSTRACT
OBJECTIVE@#To identify a full length c DNA sequence of a novel tetraspanin (TSP) homologue from Spirometra erinaceieuropaei and to predict the structure and function of its encoding protein using bioinformatics methods.@*METHODS@#Using the NCBI, EMBI, Expasy and other online sites, the open reading frame (ORF), conserved domain, physical and chemical parameters, signal peptide, transmembrane domain, epitope, topological structures of the protein sequences were predicted. And Vector NTI software was used for multiple sequence alignment and phylogenetic tree construction.@*RESULTS@#The target sequence was 1132 bp length with a 681 bpbiggest ORF encoding 226 amino acids protein with typical TSP conserved domain. It was confirmed as full length c DNA of TSP16 from Spirometra erinaceieuropaei and named as SeTSP16 (GenBank accession number: JF728872). The predicted molecular weight and isoelectric point of the deduced protein were 24 750.5 Da and 7.88 Da, respectively. Compared with TSP16s from Schistosoma japonicum and Schistosoma mansoni, it showed similarity of 59% and 59%, respectively. SeTSP16 contained four transmembrane domains (TM1-4), intracellular N and C-termini, one short small extracellular loop and one large extracellular loop. Four major epitopes that were significant different from the corresponding epitope regions of TSP16 from Schistosoma mansoni and Schistosoma japonicum were predicted.@*CONCLUSIONS@#The full length c DNA sequences of SeTSP16 are identified. It encodes a transmembrane protein which might be an ideal diagnosis antigen and target molecule for antiparasitic drugs.